A nurse is meeting with the caregivers of a client who has Alzheimer's disease who is at risk for wandering. Which of the following are manifestations that put the client at risk for wandering that the nurse should educate their caregivers about?

A. "Medications for Alzheimer's disease will help to increase my energy levels": This statement is not accurate. Medications for Alzheimer's disease, such as cholinesterase inhibitors (e.g., donepezil, rivastigmine) and memantine, are not intended to increase energy levels. Their primary goal is to improve cognitive function and help manage symptoms associated with Alzheimer's disease, but they do not directly affect energy levels.

B. "Medications for Alzheimer's disease will help slow the progression of my disease": This statement is correct. Medications used to treat Alzheimer's disease, such as cholinesterase inhibitors and memantine, are aimed at slowing the progression of cognitive decline and managing symptoms associated with the disease. While these medications cannot cure Alzheimer's disease, they can help improve cognitive function and quality of life for some individuals.

C. "Medications for Alzheimer's disease will help me remember what I forgot": This statement oversimplifies the effects of Alzheimer's medications. While these medications may help improve memory and cognition to some extent, they are not capable of restoring lost memories or reversing the effects of significant memory impairment caused by Alzheimer's disease.

D. "Medications for Alzheimer's disease will cure the disease": This statement is incorrect. Currently, there is no cure for Alzheimer's disease. Medications used to treat Alzheimer's, such as cholinesterase inhibitors and memantine, can help manage symptoms and slow disease progression, but they do not cure the underlying condition.

A. Diabetes mellitus: An inverse association between diabetes mellitus (DM) and abdominal aortic aneurysm (AAA) risk hasbeen reported. Apart from a lower AAA prevalence among patients with vsthose without DM, there isdata showing that DM may exert a protective role on aneurysmal growth in patients with small AAAs, thus decreasing the risk of rupture. As atherosclerosis has almost the same risk factors as aneurysms, the decreased AAA prevalence in patients with DM may indicate that atherosclerosis is an associated feature and not a cause of the aneurysms.

B. Total cholesterol 170 mg/dL (less than 200 mg/dL): While elevated total cholesterol is a risk factor for cardiovascular disease, it is not specifically listed as a risk factor for abdominal aortic aneurysm (AAA). However, dyslipidemia, including elevated total cholesterol levels, can contribute to the development of atherosclerosis, which is a risk factor for AAA.

C. HDL cholesterol 65 mg/dL (male greater than 45 mg/dL; female greater than 55 mg/dL): High-density lipoprotein (HDL) cholesterol levels greater than 65 mg/dL are not listed as a risk factor for abdominal aortic aneurysm (AAA). However, low levels of HDL cholesterol are associated with an increased risk of cardiovascular disease, which may indirectly contribute to the development of AAA through the promotion of atherosclerosis.

D. Smoking cigarettes: Smoking cigarettes is a significant modifiable risk factor for abdominal aortic aneurysm (AAA). Smoking damages the walls of blood vessels, promotes inflammation, and accelerates the development of atherosclerosis, increasing the risk of AAA formation and rupture.

E. Family history of aneurysm: A family history of aneurysm, particularly abdominal aortic aneurysm (AAA), is a risk factor for developing AAA. Genetic factors can predispose individuals to the development of aneurysms, and a positive family history increases the likelihood of AAA occurrence.